Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Active, not recruiting · Phase 2 · NCT05822752
Conditions: Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $282,470
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 130
About the trial
- Sponsor
- AbbVie
- Tested
- Budigalimab (drug), Livmoniplimab (drug), Lenvatinib (drug), Sorafenib (drug)
- Dates
- Started 2023-09-21; completion 2026-11
- Results posted
- Not yet
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, or sorafenib. Approximate…
From ClinicalTrials.gov, last updated 2025-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $282,470 in research payments for this study in 2025 (47 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ari D. Baron, M.D. Specialist · San Francisco, CA
- Richard S. Finn, MD Hematology & Oncology · Santa Monica, CA
- Ahmed Zakari, MD Hematology · Altamonte Springs, FL
- Joseph W. Franses, MD Medical Oncology · Chicago, IL
- Thomas A. Abrams, M.D. Medical Oncology · Boston, MA
- Reena Salgia, M.D. Gastroenterology · Detroit, MI
- Moh'd M. Khushman, MD Medical Oncology · Saint Louis, MO
- Nina Beri, M.D. Hematology & Oncology · New York, NY
- Ashwin Somasundaram Medical Oncology · Pittsburgh, PA
- Khaldoun Almhanna, MD, MPH Hematology & Oncology · Providence, RI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Adventhealth Orlando, FL $52,148
- New York University $44,476
- Washington University $43,074
- Rhode Island Hospital, RI $40,373
- The University of Chicago $34,514
- Dana Farbermass General Brigham $28,850
- Resnick Neuropsychiatric Hospital at UCLA, CA $13,356
- California PAcific Medical Center- Van Ness Campus, CA $10,757
- University of North Carolina $10,112
- $3,150
- Henry Ford Health Hospital, MI $1,660
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.